LISANNE K.A. NEIJENHUIS^1,2,3,#, LEUTA L. NAUMANN^4,#, SONIA A.M. FERKEL¹, SAMUEL J.S. RUBIN¹, STEPHAN ROGALLA^1,*

Oncology Research, Vol.32, No.7, pp. 1163-1172, 2024, DOI:10.32604/or.2024.050907 - 20 June 2024

Abstract Background: Osteosarcoma is the most common malignant primary bone tumor. The prognosis for patients with disseminated disease remains very poor despite recent advancements in chemotherapy. Moreover, current treatment regimens bear a significant risk of serious side effects. Thus, there is an unmet clinical need for effective therapies with improved safety profiles. Taurolidine is an antibacterial agent that has been shown to induce cell death in different types of cancer cell lines. Methods: In this study, we examined both the antineoplastic and antiangiogenic effects of taurolidine in animal models of osteosarcoma. K7M2 murine osteosarcoma cells were… More >

QIUQIANG CHEN^1,*, XUEJUN GUO², WENXUE MA^3,*

Oncology Research, Vol.32, No.1, pp. 49-60, 2024, DOI:10.32604/or.2023.042383 - 15 November 2023

Abstract Cancer immunotherapy has emerged as a promising strategy for the treatment of cancer, with the tumor microenvironment (TME) playing a pivotal role in modulating the immune response. CD47, a cell surface protein, has been identified as a crucial regulator of the TME and a potential therapeutic target for cancer therapy. However, the precise functions and implications of CD47 in the TME during immunotherapy for cancer patients remain incompletely understood. This comprehensive review aims to provide an overview of CD47’s multifaced role in TME regulation and immune evasion, elucidating its impact on various types of immunotherapy… More > Graphic Abstract

ABHISHEK WAHI¹, MAMTA BISHNOI², NEHA RAINA¹, MEGHNA AMRITA SINGH¹, PIYUSH VERMA¹, PIYUSH KUMAR GUPTA^3,4, GINPREET KAUR⁵, HARDEEP SINGH TULI^6,*, MADHU GUPTA^1,*

Oncology Research, Vol.32, No.1, pp. 19-47, 2024, DOI:10.32604/or.2023.042228 - 15 November 2023

Abstract Cancer is a leading cause of death globally, with limited treatment options and several limitations. Chemotherapeutic agents often result in toxicity which long-term conventional treatment. Phytochemicals are natural constituents that are more effective in treating various diseases with less toxicity than the chemotherapeutic agents providing alternative therapeutic approaches to minimize the resistance. These phytoconstituents act in several ways and deliver optimum effectiveness against cancer. Nevertheless, the effectiveness of phyto-formulations in the management of cancers may be constrained due to challenges related to inadequate solubility, bioavailability, and stability. Nanotechnology presents a promising avenue for transforming current… More > Graphic Abstract

DHANYA K. NAMBIAR¹, DEEPALI MISHRA², RANA P. SINGH^2,3,*

Oncology Research, Vol.31, No.4, pp. 405-421, 2023, DOI:10.32604/or.2023.028310 - 25 June 2023

Abstract Ionizing radiation is frequently used to treat solid tumors, as it causes DNA damage and kill cancer cells. However, damaged DNA is repaired involving poly-(ADP-ribose) polymerase-1 (PARP-1) causing resistance to radiation therapy. Thus, PARP-1 represents an important target in multiple cancer types, including prostate cancer. PARP is a nuclear enzyme essential for single-strand DNA breaks repair. Inhibiting PARP-1 is lethal in a wide range of cancer cells that lack the homologous recombination repair (HR) pathway. This article provides a concise and simplified overview of the development of PARP inhibitors in the laboratory and their clinical More > Graphic Abstract

LEI SUN^1,2, YUE ZHANG³, YUQIN YAO⁴, HONGLIN DU³, YUEHUA ZHANG¹, AIPING FANG^1,2,*

Oncology Research, Vol.29, No.3, pp. 175-187, 2021, DOI:10.32604/or.2022.03550 - 01 August 2022

Abstract Long intergenic non-protein coding RNA 1124 (LINC01124) has been identified as an important regulator of non-small-cell lung cancer. However, the expression and detailed role of LINC01124 in hepatocellular carcinoma (HCC) remain unestablished to date. Therefore, this study aimed to elucidate the role of LINC01124 in the aggressiveness of HCC cells and identify the underlying regulatory mechanism. Quantitative reverse transcriptase-polymerase chain reaction was performed to measure the expression of LINC01124 in HCC. Cell Counting Kit-8 assay, Transwell cell migration and invasion assays, and a xenograft tumor model were used to investigate the function of LINC01124 in… More >

Pedro Fong^*1, Cheng N. Ao^*†1, Kai I. Tou^*, Ka M. Huang^*, Chi C. Cheong^*, Li R. Meng^*

Oncology Research, Vol.27, No.2, pp. 237-251, 2019, DOI:10.3727/096504018X15235274183790

Abstract The aim of this study was to investigate the inhibition effects of cordycepin and its derivatives on endometrial cancer cell growth. Cytotoxicity MTT assays, clonogenic assays, and flow cytometry were used to observe the effects on apoptosis and regulation of the cell cycle of Ishikawa cells under various concentrations of cordycepin, cisplatin, and combinations of the two. Validated in silico docking simulations were performed on 31 cordycepin derivatives against adenosine deaminase (ADA) to predict their binding affinities and hence their potential tendency to be metabolized by ADA. Cordycepin has a significant dose-dependent inhibitory effect on More >